Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 8:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 35 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Viral Upper Respiratory Tract Infection Clear all
Terminated Phase 1Phase 2 Interventional Results available

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

NCT04933968
View directory record Official record
Conditions
Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
Interventions
ALVR106, Placebo
Biological
Lead sponsor
AlloVir
Industry
Eligibility
17 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Jul 22, 2026, 8:16 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Immune Defense Protein Impact On Respiratory Immune Outcomes

NCT07431840
View directory record Official record
Conditions
Upper Respiratory Disease, Influenza, Viral Upper Respiratory Infection
Interventions
Immune Defense Protein 50mg Dose, IDP 200mg Dose, Matching Placebo
Dietary Supplement
Lead sponsor
Quantec Ltd
Industry
Eligibility
60 Years and older
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 22, 2026, 8:16 PM EDT
Recruiting Phase 2 Interventional

Omalizumab Before Onset of Exacerbations

NCT05332067
View directory record Official record
Conditions
Asthma in Children, Atopy, Viral Upper Respiratory Infection
Interventions
Omalizumab, Placebo
Drug
Lead sponsor
Children's National Research Institute
Other
Eligibility
6 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jul 22, 2026, 8:16 PM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

ARMS-I (a Formulation of Cetylpyridinium Chloride -CPC)

NCT03026205
View directory record Official record
Conditions
Viral Upper Respiratory Tract Infection
Interventions
ARMS-I
Drug
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years to 45 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Jul 22, 2026, 8:16 PM EDT
Withdrawn Phase 3 Interventional

Azithromycin Plus Hydroxychloroquine for COVID-19 Infection

NCT05026801
View directory record Official record
Conditions
Respiratory Tract Infection Viral
Interventions
Azithromycin plus hydroxychloroquine
Drug
Lead sponsor
Iterum Therapeutics, International Limited
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Waterbury, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Jul 22, 2026, 8:16 PM EDT
Recruiting Phase 3 Interventional

Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

NCT03808922
View directory record Official record
Conditions
Lower Respiratory Tract Infection, Parainfluenza, Immunocompromised, COVID-19
Interventions
DAS181, Placebo, DAS181 COVID-19, DAS181 OL
Drug
Lead sponsor
Ansun Biopharma, Inc.
Industry
Eligibility
Not listed
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
23
States / cities
Duarte, California • Sacramento, California • Chicago, Illinois + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 22, 2026, 8:16 PM EDT
Active, not recruiting Not applicable Interventional

Rapid Diagnosis of Viral Acute Respiratory Infection to Decrease Unnecessary Antibiotic Utilization in the Emergency Department (RADIATE)

NCT06271655
View directory record Official record
Conditions
Acute Respiratory Infection, Viral Infection, Upper Respiratory Tract Infections
Interventions
SPOTFIRE R Panel
Device
Lead sponsor
Christopher Payette
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Nov 20, 2025 · Synced Jul 22, 2026, 8:16 PM EDT
Not listed No phase listed Observational

Change in Antibody Levels Following SARS-CoV-2 (Covid-19) Vaccinations

NCT04944095
View directory record Official record
Conditions
Covid-19, Subjects Vaccinated Against Covid-19
Interventions
Change in SARS-CoV-2 Antibody Levels
Other
Lead sponsor
Dr. Sidney J. Stohs
Other
Eligibility
55 Years and older
Enrollment
10,000 participants
Timeline
2021 – 2024
U.S. locations
1
States / cities
Southlake, Texas
Source: ClinicalTrials.gov public record
Updated Aug 28, 2022 · Synced Jul 22, 2026, 8:16 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Non-invasive Biometric Monitoring in Nursing Homes to Fight COVID-19

NCT04548895
View directory record Official record
Conditions
Covid19, Community-Acquired Respiratory Tract Infection
Interventions
Observational measurement of biometric data. No change to health care provided.
Device
Lead sponsor
Health Stream Analytics, LLC
Industry
Eligibility
Not listed
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pasco, Washington
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Phase 1 Interventional

Respiratory Syncytial Virus Human Challenge in Healthy Adult Volunteers

NCT02484417
View directory record Official record
Conditions
Upper Respiratory Tract Infection
Interventions
RSV A2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Jul 22, 2026, 8:16 PM EDT
Completed No phase listed Observational

Study to Evaluate the Incidence of Hospitalizations and Respiratory Tract Infections in Premature Infants

NCT00384462
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Not listed
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Month to 6 Months
Enrollment
346 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
59
States / cities
Birmingham, Alabama • Benton, Arkansas • Jonesboro, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Phase 1 Interventional

Alleviation of Common Cold Symptoms

NCT06106880
View directory record Official record
Conditions
Common Cold, Pharyngitis, Fever, Congestion, Rhinorrhea, Cough, Sore-throat, Sore Throats Viral, Malaise, Headache, Runny Nose, Sneezing
Interventions
Wintergreen Throat Spray and Aspirin Tablet, Aspirin Throat Spray and Placebo Tablet, Wintergreen Throat Spray and Placebo Tablet, Placebo Throat Spray and Placebo Tablet
Drug · Dietary Supplement · Other
Lead sponsor
Applied Biological Laboratories Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
6
States / cities
Irvine, California • Washington D.C., District of Columbia • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2024 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Phase 4 Interventional Results available

Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds

NCT00189475
View directory record Official record
Conditions
Upper Respiratory Infection
Interventions
Montelukast, Placebo
Drug
Lead sponsor
Deborah Gentile
Other
Eligibility
18 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection

NCT06065176
View directory record Official record
Conditions
COVID-19, Vaccine-Preventable Diseases, SARS CoV 2 Infection, Upper Respiratory Tract Infection, Upper Respiratory Disease
Interventions
Novavax COVID-19 vaccine (2023-2024 formula XBB containing), Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)
Biological
Lead sponsor
Sarang K. Yoon, DO, MOH
Other
Eligibility
18 Years and older
Enrollment
1,188 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Jul 22, 2026, 8:16 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Longitudinal Deep Phenotyping of Central Mechanisms in Dysosmia: A Pilot Study Using Electrobulbogram (EBG), Functional MRI (fMRI), and Diffusion-Weighted Imaging (DWI)

NCT07149428
View directory record Official record
Conditions
Respiratory Tract Infection, Smell Disorder, Influenza, Rhinosinusitis, COVID-19, Depression, Parosmia, Hyposomia, Normosomia, Anosmia
Interventions
Not listed
Lead sponsor
National Institute on Deafness and Other Communication Disorders (NIDCD)
NIH
Eligibility
18 Years to 99 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Immunogenicity, Safety and Tolerability of Adjuvanted and Non-Adjuvanted H2N3 Influenza Vaccines in Adults

NCT05875961
View directory record Official record
Conditions
Influenza, Human, Infections, Respiratory Tract Infections, Virus Diseases, Infection Viral
Interventions
Low dose A/H2N3c + standard dose MF59, Intermediate dose A/H2N3c + standard dose MF59, High dose A/H2N3c + standard dose MF59, High dose A/H2N3c non-adjuvanted, Lowest dose A/H2N3c + high dose MF59, Low dose A/H2N3c + high dose MF59
Biological
Lead sponsor
Seqirus
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
3
States / cities
Rockville, Maryland • Lincoln, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Jul 22, 2026, 8:16 PM EDT
Recruiting Not applicable Interventional

Reducing Overuse of Antibiotics With Decision Support

NCT06788093
View directory record Official record
Conditions
Lower Respiratory Tract Infection, Pneumonia, Asthma, Bronchiolitis, Viral
Interventions
ED Clinical Decision Support (CDS-ED), Transitions Clinical Decision Support (CDS-Tr)
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Months to 17 Years
Enrollment
2,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
3
States / cities
Oakland, California • San Francisco, California • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Not applicable Interventional Results available

Rapid Diagnostics for Upper Respiratory Infections in the Emergency Department

NCT02957136
View directory record Official record
Conditions
Respiratory Tract Infections, Influenza, Human, Common Cold
Interventions
Rapid respiratory pathogen nucleic acid amplification test
Device
Lead sponsor
University of California, Davis
Other
Eligibility
1 Year to 101 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Jul 22, 2026, 8:16 PM EDT
Completed No phase listed Observational

Impact of Respiratory Pathogens in Infants

NCT01789268
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
Respiratory Inductive Plethysmography
Device
Lead sponsor
University of Rochester
Other
Eligibility
0 Days to 3 Years
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Jul 22, 2026, 8:16 PM EDT
Not listed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831

NCT04480333
View directory record Official record
Conditions
Covid19, Corona Virus Infection, Severe Acute Respiratory Syndrome, Severe Acute Respiratory Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Severe Acute Respiratory Syndrome of Upper Respiratory Tract, Neurodegeneration, Neuroinflammatory Response
Interventions
Drug: NA-831 - 0.10 mg/kg, Placebo- 0.10 mg/kg, Drug: NA-831 - 0.20 mg/kg, Placebo- 0.20 mg/kg, Drug: GS-5734 - 1.00 mg/kg, Placebo- 1.00 mg/kg, Drug: GS-5734 - 2.00 mg/kg, Placebo- 2.00 mg/kg, Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg), Placebo 0.10 mg + 1.00 mg/kg, Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg), Placebo 0.20 mg + 2.00 mg/kg
Drug · Combination Product
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Sunnyvale, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2020 · Synced Jul 22, 2026, 8:16 PM EDT
Terminated Phase 4 Interventional

A Pragmatic Randomized Trial of Icosapent Ethyl for High-Cardiovascular Risk Adults

NCT04505098
View directory record Official record
Conditions
Covid19, Atherosclerosis, Cardiovascular Diseases, Upper Respiratory Tract Infections
Interventions
Icosapent ethyl
Drug
Lead sponsor
Kaiser Permanente
Other
Eligibility
50 Years and older
Enrollment
39,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Spirulina Oral Supplement for Enhancing Host Resilience to Virus Infection

NCT05447078
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Immulina TM, Placebo
Drug · Dietary Supplement
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Enrollment
492 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Dec 25, 2025 · Synced Jul 22, 2026, 8:16 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

New Reusable Mask Design With Superior Filtration and Fit

NCT04826809
View directory record Official record
Conditions
Covid19, Tuberculosis, Respiratory Viral Infection
Interventions
N95 mask, Nordell single E-100 layer mask, Nordell double E-100 layer mask
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Mankato, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Jul 22, 2026, 8:16 PM EDT
Completed No phase listed Observational Results available

The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years

NCT00405509
View directory record Official record
Conditions
Upper Respiratory Infection, Common Cold
Interventions
Not listed
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
6 Years to 13 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Jul 22, 2026, 8:16 PM EDT